Are Autologous Therapies Here To Stay? Are Allogeneic Therapies The Future?

The pros, cons and future of allogeneic versus autologous therapies are explored as Rachel Smith, Portfolio Director for Veristat, shares her observations on the impact of these techniques on advanced cell-based therapies and what the next decade may hold. Factors spanning patient safety, manufacturing, costs and regulations are considered as Rachel responds to the question whether an autologous approach for rare disease therapies is sustainable long-term.